IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).

Michel Ducreux,Andrew X. Zhu,Ann-Lii Cheng,Peter R. Galle,Masafumi Ikeda,Alan Nicholas,Wendy Verret,Lindong Li,Vincent E. Gaillard,Riccardo Lencioni,Richard S. Finn

IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).

2021

Michel Ducreux
Andrew X. Zhu
Ann-Lii Cheng
Peter R. Galle
Masafumi Ikeda
Alan Nicholas
Wendy Verret
Lindong Li
Vincent E. Gaillard
Riccardo Lencioni
Richard S. Finn

4071Background: Based on IMbrave150 (NCT03434379) results, atezo + bev has been approved in > 60 countries for pts with unresectable HCC who have not received prior systemic therapy (Finn RS, NEJM ...

Keywords:

Internal medicine
exploratory analysis
treatment response
Hepatocellular carcinoma
Systemic therapy
Medicine
Oncology
in patient
Bevacizumab
Sorafenib
Atezolizumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations